Cargando…
Psychometric Validation of the Haemo-QOL-A in Participants with Hemophilia A Treated with Gene Therapy
PURPOSE: The hemophilia-specific health-related quality of life (HRQOL) questionnaire (Haemo-QOL-A) is validated for detecting QOL changes following standard therapy for hemophilia A, but has not been rigorously evaluated after gene therapy. This post hoc analysis evaluated the psychometric properti...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307866/ https://www.ncbi.nlm.nih.gov/pubmed/35879931 http://dx.doi.org/10.2147/PROM.S357555 |
_version_ | 1784752856267489280 |
---|---|
author | Quinn, Jennifer Delaney, Kathleen A Wong, Wing Yen Miesbach, Wolfgang Bullinger, Monika |
author_facet | Quinn, Jennifer Delaney, Kathleen A Wong, Wing Yen Miesbach, Wolfgang Bullinger, Monika |
author_sort | Quinn, Jennifer |
collection | PubMed |
description | PURPOSE: The hemophilia-specific health-related quality of life (HRQOL) questionnaire (Haemo-QOL-A) is validated for detecting QOL changes following standard therapy for hemophilia A, but has not been rigorously evaluated after gene therapy. This post hoc analysis evaluated the psychometric properties of Haemo-QOL-A in adult people with severe hemophilia A (PWSHA) receiving valoctocogene roxaparvovec (AAV5-hFVIII-SQ) in 2 clinical trials (phase 1/2, NCT02576795; phase 3, NCT03370913). PATIENTS AND METHODS: Adult PWSHA (factor VIII levels ≤1 IU/dL) received 1 AAV5-hFVIII-SQ infusion (6×10(13) vg/kg). Participants were assessed using the Haemo-QOL-A and the EuroQOL (EQ)-5D-5L and visual analog scale (VAS) questionnaires pre- and post-infusion. Psychometric analyses included convergent and discriminant validity, internal consistency, and reliability. Clinically important difference (CID) was estimated using 3-point change in EQ-5D-5L VAS as anchor. RESULTS: Haemo-QOL-A data were analyzed from 7 (phase 1/2, 3-year follow-up) and 16 participants (phase 3, 26-week analysis). Change in Haemo-QOL-A Total Scores correlated with EQ-5D-5L VAS score change at 26 weeks (Pearson’s correlation 0.77). At 26 weeks, increased Haemo-QOL-A Physical Functioning was associated with decreased EQ-5D-5L Pain and Discomfort and decreased Anxiety and Depression (Spearman’s Rank correlations −0.73 and −0.62, respectively, P <0.01). Internal consistency analysis showed good reliability for all domains (Cronbach’s alpha >0.7) except Treatment Concern (Cronbach’s alpha = 0.31). Anchor-based CID estimates were met for Haemo-QOL-A Total Score (≥5.5) and domain scores (≥6) for Consequences of Bleeding, Physical Functioning, Role Functioning, and Worry. CONCLUSION: Our preliminary results suggest that the Haemo‐QOL‐A is a valid, reliable instrument for HRQOL assessment in PWSHA undergoing gene therapy. Future research should be undertaken to confirm these findings in a larger number of participants. |
format | Online Article Text |
id | pubmed-9307866 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-93078662022-07-24 Psychometric Validation of the Haemo-QOL-A in Participants with Hemophilia A Treated with Gene Therapy Quinn, Jennifer Delaney, Kathleen A Wong, Wing Yen Miesbach, Wolfgang Bullinger, Monika Patient Relat Outcome Meas Original Research PURPOSE: The hemophilia-specific health-related quality of life (HRQOL) questionnaire (Haemo-QOL-A) is validated for detecting QOL changes following standard therapy for hemophilia A, but has not been rigorously evaluated after gene therapy. This post hoc analysis evaluated the psychometric properties of Haemo-QOL-A in adult people with severe hemophilia A (PWSHA) receiving valoctocogene roxaparvovec (AAV5-hFVIII-SQ) in 2 clinical trials (phase 1/2, NCT02576795; phase 3, NCT03370913). PATIENTS AND METHODS: Adult PWSHA (factor VIII levels ≤1 IU/dL) received 1 AAV5-hFVIII-SQ infusion (6×10(13) vg/kg). Participants were assessed using the Haemo-QOL-A and the EuroQOL (EQ)-5D-5L and visual analog scale (VAS) questionnaires pre- and post-infusion. Psychometric analyses included convergent and discriminant validity, internal consistency, and reliability. Clinically important difference (CID) was estimated using 3-point change in EQ-5D-5L VAS as anchor. RESULTS: Haemo-QOL-A data were analyzed from 7 (phase 1/2, 3-year follow-up) and 16 participants (phase 3, 26-week analysis). Change in Haemo-QOL-A Total Scores correlated with EQ-5D-5L VAS score change at 26 weeks (Pearson’s correlation 0.77). At 26 weeks, increased Haemo-QOL-A Physical Functioning was associated with decreased EQ-5D-5L Pain and Discomfort and decreased Anxiety and Depression (Spearman’s Rank correlations −0.73 and −0.62, respectively, P <0.01). Internal consistency analysis showed good reliability for all domains (Cronbach’s alpha >0.7) except Treatment Concern (Cronbach’s alpha = 0.31). Anchor-based CID estimates were met for Haemo-QOL-A Total Score (≥5.5) and domain scores (≥6) for Consequences of Bleeding, Physical Functioning, Role Functioning, and Worry. CONCLUSION: Our preliminary results suggest that the Haemo‐QOL‐A is a valid, reliable instrument for HRQOL assessment in PWSHA undergoing gene therapy. Future research should be undertaken to confirm these findings in a larger number of participants. Dove 2022-07-18 /pmc/articles/PMC9307866/ /pubmed/35879931 http://dx.doi.org/10.2147/PROM.S357555 Text en © 2022 Quinn et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Quinn, Jennifer Delaney, Kathleen A Wong, Wing Yen Miesbach, Wolfgang Bullinger, Monika Psychometric Validation of the Haemo-QOL-A in Participants with Hemophilia A Treated with Gene Therapy |
title | Psychometric Validation of the Haemo-QOL-A in Participants with Hemophilia A Treated with Gene Therapy |
title_full | Psychometric Validation of the Haemo-QOL-A in Participants with Hemophilia A Treated with Gene Therapy |
title_fullStr | Psychometric Validation of the Haemo-QOL-A in Participants with Hemophilia A Treated with Gene Therapy |
title_full_unstemmed | Psychometric Validation of the Haemo-QOL-A in Participants with Hemophilia A Treated with Gene Therapy |
title_short | Psychometric Validation of the Haemo-QOL-A in Participants with Hemophilia A Treated with Gene Therapy |
title_sort | psychometric validation of the haemo-qol-a in participants with hemophilia a treated with gene therapy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307866/ https://www.ncbi.nlm.nih.gov/pubmed/35879931 http://dx.doi.org/10.2147/PROM.S357555 |
work_keys_str_mv | AT quinnjennifer psychometricvalidationofthehaemoqolainparticipantswithhemophiliaatreatedwithgenetherapy AT delaneykathleena psychometricvalidationofthehaemoqolainparticipantswithhemophiliaatreatedwithgenetherapy AT wongwingyen psychometricvalidationofthehaemoqolainparticipantswithhemophiliaatreatedwithgenetherapy AT miesbachwolfgang psychometricvalidationofthehaemoqolainparticipantswithhemophiliaatreatedwithgenetherapy AT bullingermonika psychometricvalidationofthehaemoqolainparticipantswithhemophiliaatreatedwithgenetherapy |